Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms
Conditions
Vasomotor Symptoms, Endometrial Safety
Trial Timeline
Feb 1, 2002 → May 1, 2004
NCT ID
NCT00332553About Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol is a phase 2 stage product being developed by Eli Lilly for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00332553. Target conditions include Vasomotor Symptoms, Endometrial Safety.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00332553 | Phase 2 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms